AstraZeneca PLC (LON:AZN), a leading global biopharmaceutical company with a market capitalization of $216.74 billion, has been making significant strides in the pharmaceutical industry, particularly ...

Dear reader, China’s biotechnology sector has rapidly emerged as one of the fastest-growing industries, with Chinese players ...

The global neuromuscular disease therapeutics market is projected to grow by $13.73 billion between 2025 and 2029, according ...

A cluster that so far comprises fewer than 60 companies could have the potential to deliver nearly £900m to the region's economy ...

The 12th edition of the World Governments Summit will take place in Dubai from 11th to 13th February 2025, under the theme ...

Resbiotic Nutrition Inc. ("resbiotic" or "res"), a leading provider of physician-formulated and science-backed dietary supplements, has announced a strategic distribution agreement with Grupo Columbia ...

BIOTRONIK Neuro will unveil new data from the BENEFIT-03 clinical study at the North American Neuromodulation Society (NANS) 2025 Annual Meeting. The findings highlight the transformative potential of ...

Use precise geolocation data and actively scan device characteristics for identification. This is done to store and access ...

Flagship Harbor Advisors LLC lowered its holdings in AstraZeneca PLC (NASDAQ:AZN – Free Report) by 2.5% during the 4th ...

AstraZeneca and Daiichi Sankyo ’s antibody-drug conjugate (ADC) Enhertu (trastuzumab deruxtecan) has received approval from ...

AstraZeneca achieves top rankings as Best Place to Work across North Africa and Levant in 2024 data-link= achieves top rankings as Best ...

CMS said it is considering ways to bring "greater transparency" to the Medicare drug pricing negotiation program mandated ...